In September, QUOD travelled to Istanbul, Turkey, to attend The Transplantation Society 2024 (TTS2024) Congress. This was the first time that QUOD had participated at the biennial event, which enabled us to connect with a huge number of transplant professionals from across the world. It was a wonderful opportunity to catch up with QUOD colleagues as well as researchers who had used QUOD previously and were attending the congress. We had a lot of visitors and interest in our exhibition stand and we were able to promote the bioresource to a wide audience.
The TTS2024 programme was jam packed, with a wealth of novel research and new ideas being presented, sparking stimulating discussions. We were excited to see research using QUOD samples featured in an e-poster from Hussain Abbas. QUOD supplied samples from >1,000 liver donors to this study, which revealed differences between DBD and DCD donors and highlighted the under-utilisation of DCD livers as well as preretrieval biochemical and metabolic derangements that contribute to the risk factors associated with DCD livers.
TTS2024 was a huge success and opened up the opportunity to connect and showcase QUOD internationally.